Loss of IFN-γ enables the expansion of autoreactive CD4+ T cells to induce experimental autoimmune encephalomyelitis by a nonencephalitogenic myelin variant antigen

Journal of Immunology

Volumn 180, Issue 7, 2008, Pages 4451-4457

  Sabatino Jr , Joseph J ^a   Shires, John ^b   Altaian, John D ^a,c   Ford, Mandy L ^a   Evavold, Brian D ^a,b  

^a Department of Microbiology and Immunology ^*  (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 17; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; HISTOCOMPATIBILITY ANTIGEN; INTERFERON RECEPTOR; MYELIN ASSOCIATED GLYCOPROTEIN; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DISEASE SEVERITY; FEMALE; IMMUNIZATION; INFLAMMATORY INFILTRATE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SPLEEN CELL; ANIMAL; AUTOIMMUNITY; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE MUTANT;

ANIMALS; AUTOIMMUNITY; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HISTOCOMPATIBILITY ANTIGENS; INTERFERON TYPE II; INTERLEUKIN-17; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELIN-ASSOCIATED GLYCOPROTEIN; RECEPTORS, INTERFERON;

EID: 44449165047     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.7.4451     Document Type: Article

References (37)

1. Evavold, B. D., J. Sloan-Lancaster, and P. M. Allen. 1993. Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands. Immunol. Today 14: 602-609.
2. Sloan-Lancaster, J., B. D. Evavold, and P. M. Allen. 1993. Induction of T-cell anergy by altered T-cell-receptor ligand on live antigen-presenting cells. Nature 363: 156-159.
3. + T cell anergy in vitro. J. Exp. Med. 187: 89-96.
4. De Magistris, M. T., J. Alexander, M. Coggeshall, A. Altaian, F. C. A. Gaeta, H. M. Grey, and A. Sette. 1992. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68: 625-634.
5. Ford, M. L., and B. D. Evavold. 2003. Regulation of polyclonal T cell responses by an MHC anchor-substituted variant of myelin oligodendrocyte glycoprotein 35-55. J. Immunol. 171: 1247-1254.
6. Bielekova, B., B. Goodwin, N. Richert, I. Cortese, T. Kondo, G. Afshar, B. Gran, J. Eaton, J. Antel, J. A. Frank, et al. 2000. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6: 1167-1175.
7. Kim, H. J., J. P. Antel, P. Duquette, D. G. Alleva, P. J. Conlon, and A. Bar-Or. 2002. Persistence of immune responses to altered and native myelin antigens in patients with multiple sclerosis treated with altered peptide ligand. Clin. Immunol. 104: 105-114.
8. Nicholson, L. B., J.M. Greer, R. A. Sobel, M. B. Lees, and V. K. Kuchroo. 1995. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 3: 397-405.
9. Kappos, L., G. Comi, H. Panitch, J. Oger, J. Antel, P. Conlon, and L. Steinman. 2000. Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial: the altered peptide ligand in relapsing MS study group. Nat. Med. 6: 1176-1182.
10. Margot, C. D., M. L. Ford, and B. D. Evavold. 2005. Amelioration of established experimental autoimmune encephalomyelitis by an MHC anchor-substituted variant of proteolipid protein 139-151. J. Immunol. 174: 3352-3358.
11. Ford, M. L., and B. D. Evavold. 2004. An MHC anchor-substituted analog of myelin oligodendrocyte glycoprotein 35-55 induces IFN-γ and autoantibodies in the absence of experimental autoimmune encephalomyelitis and optic neuritis. Eur. J. Immunol. 34: 388-397.
12. Ferber, I. A., S. Brocke, C. Taylor-Edwards, W. Ridgway, C. Dinisco, L. Steinman, D. Dalton, and C. G. Fathman. 1996. Mice with a disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomy- elitis (EAE). J. Immunol. 156: 5-7.
13. Krakowski, M., and T. Owens. 1996. Interferon-y confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26: 1641-1646.
14. Willenborg, D. O., S. Fordham, C. C. Bernard, W. B. Cowden, and I. A. Ramshaw. 1996. IFN-γ plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157: 3223-3227.
15. Chu, C. Q., S. Wittmer, and D. K. Dalton. 2000. Failure to suppress the expansion of the activated CD4 T cell population in interferon γ-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. 192:123-128.
16. Tran, E. H., E. N. Prince, and T. Owens. 2000. Interferon-γ shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164: 2759-2768.
17. Jelinsky, S. A., J. S. Miyashiro, K. A. Saraf, C. Tunkey, P. Reddy, J. Newcombe, J. L. Oestreicher, E. L. Brown, W. L. Trepicchio, J. P. Leonard, and S. Marusic. 2005. Exploiting genotypic differences to identify genes important for EAE development. J. Neurol. Sci. 239: 81-93.
18. + Tregs. J. Clin. Invest. 116: 2434-2441.
19. Fabis, M. J., G. S. Scott, R. B. Kean, H. Koprowski, and D. C. Hooper. 2007. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc. Natl. Acad. Sci. USA 104: 5656-5661.
20. Xiao, B., C. Ma, L. Xu, H. Link, and C. Lu. 2008. IL-12/IFN-γ/NO axis plays critical role in development of Th1-mediated experimental autoimmune encephalomyelitis. Mol. Immunol. 45: 1191-1196.
21. Chang, H. C., Z. Bao, Y. Yao, A. G. Tse, E. C. Goyarts, M. Madsen, E. Kawasaki, P. P. Brauer, J. C. Sacchettini, and S. G. Nathenson. 1994. A general method for facilitating heterodimeric pairing between two proteins: application of α and β T-cell receptor extracellular segments. Proc. Natl. Acad. Sci. USA 91: 11408-11412.
22. Donnelly, M. L., L. E. Hughes, G. Luke, H. Mendoza, E. Ten Dam, D. Gani, and M. D. Ryan. 2001. The "cleavage" activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring "2A-like" sequences. J. Gen. Virol. 82: 1027-1041.
23. Schatz, P. J. 1993. Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology 11: 1138-1143.
24. b mice. Eur. J. Immunol. 26: 2470-2479.
25. Korn, T., J. Reddy, W. Gao, E. Bettelli, A. Awasthi, T. R. Petersen, B. T. Backstrom, R. A. Sobel, K. W. Wucherpfennig, T. B. Strom, et al. 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 3: 423-431.
26. Hofstetter, H. H., S. M. Ibrahim, D. Koczan, N. Kruze, A. Weishaupt, K. V. Toyka, and R. Gold. 2005. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 237:123-130.
27. Park, H. B., Z. Li, X. O. Yang, S. H. Chang, R. Nurieva, Y. Wang, L. Hood, Z. Zhu, Q. Tian, and C. Dong. 2005. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6: 1133-1141.
28. Komiyama, Y., S. Nakae, T. Matsuki, A. Nambu, H. Ishigame, S. Kakuta, K. Sudo, andY. Iwakura. 2006. IL-17plays animportantroleinthedevelopment of experimental autoimmune encephalomyelitis. J. Immunol. 177: 566 -573.
29. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6: 1123-1132.
30. Minguela, A., S. Pastor, W. Mi, J. A. Richardson, and E. S. Ward. 2007. Feedback regulation of murine autoimmunity via dominant anti-inflammatory effects of interferon-γ. J. Immunol. 178: 134-144.
31. Willenborg, D. O., S. A. Fordham, M. A. Staykova, I. A. Ramshaw, and W. B. Cowden. 1999. IFN-γ is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J. Immunol. 163.
32. Dalton, D. K., L. Haynes, C. Q. Chu, S. L. Swain, and S. Wittmer. 2000. Inter-feron γ eliminates responding CD4 T cells during mycobacterial infection by inducing apoptosis of activated CD4 T cells. J. Exp. Med. 192: 117-122.
33. Kwidzinski, E., J. Bunse, O. Aktas, D. Richter, L. Mutlu, F. Zipp, R. Nitsch, and I. Bechman. 2005. Indolamine 2,3- dioxygenase is expressed in the CNS and downregulates autoimmune inflammation. FASEB J. 19: 1347-1349.
34. Refaeli, Y., L. van Parijs, S. I. Alexander, and A. K. Abbas. 2002. Interferon γ is required for activation-induced death of T lymphocytes. J. Exp. Med. 196:999-1005.
35. Sethna, M. P., and L. A. Lampson. 1991. Immune modulation within the brain: recruitment of inflammatory cells and increased major histocompatibility antigen expression following intracerebral injection of interferon-γ. J. Neuroimmunol. 34: 121-132.
36. Lin, W., S. L. Bailey, H. Ho, H. P. Harding, D. Ron, S. D. Miller, and B. Popko. 2007. The integrated stress response prevents demyelination by protecting oligodendrocytes against immune-mediated damage. J. Clin. Invest. 117: 448 -456.
37. Balabanov, R., K. Strand, R. Goswami, E. McMahon, W. Bogolka, S. D. Miller, and B. Popko. 2007. Interferon-γ-oligodendrocyte interaction in the regulation of experimental autoimmune encephalomyelitis. J. Neurosci. 27: 2013-2024.